Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized placebo-controlled dose-finding study of an acne mRNA vaccine in adults with moderate to severe acne
2025-521740-38-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 10
01
Overview
Phase 2, randomised trial of Acne mRNA vaccine in acne vulgaris (4 arms), sponsored by Sanofi. Primary endpoints: Number of participants with unsolicited systemic adverse events, Number of participants with solicited injection site and systemic reactions and 9 more. Planned start Jul 2026; status: authorised.
02
Drugs
Acne mRNA vaccine
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2025-521740-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521740-38-00.